Presentation is loading. Please wait.

Presentation is loading. Please wait.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt.

Published bySkylar Marler Modified over 10 years ago

Similar presentations

Presentation on theme: "Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt."— Presentation transcript:

1 Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt

2 Location of Centers Participating in the CIBMTR 2012 SUM12_22.ppt Slide 2

3 Transplants SUM12_23.ppt Slide 3 Transplant Activity in the U.S. 1980-2011

4 SUM12_24.ppt Allogeneic Stem Cell Sources by Recipient Age 2001-2010 Age 20 yrsAge 20 yrs Slide 4 Transplants, %

5 SUM12_25.ppt Autologous Stem Cell Sources by Recipient Age, 2001-2010 Age 20 yrsAge 20 yrs Slide 5 Transplants, %

6 SUM12_26.ppt Trends in Transplants by Type and Recipient Age* 2001-2010 * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6 Transplants, % Allogeneic TransplantsAutologous Transplants

7 SUM12_27.ppt Trends in Transplants by Transplant Type and Recipient Age* 1990-2010 * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 Transplants, % Allogeneic TransplantsAutologous Transplants

8 Indications for Hematopoietic Stem Cell Transplants in the United States, 2010 (Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) SUM12_28.ppt Slide 8 Number of Transplants

9 Indications for Hematopoietic Stem Cell Transplants for Age 20yrs, in the U.S., 2010 (Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants) SUM12_29.ppt Slide 9 Number of Transplants

10 SUM12_30.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR, 1993-2010 - by Donor Type and Graft Source - Slide 10 Number of Transplants

11 Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR, 1993-2010 - by Donor Type and Graft Source - Slide 11 Number of Transplants SUM12_31.ppt

12 Unrelated Donor Stem Cell Sources by Recipient Age 2001-2010 Age 20 yrsAge 20 yrs Slide 12 Transplants, % SUM12_32.ppt

13 Unrelated Cord Blood Transplants by Age Registered with the CIBMTR 2001-2010 Slide 13 Number of Transplants * * Data incomplete SUM12_33.ppt

14 One-Year Survival, % Slide 14 One-year Survival by Year of Transplant, Donor and Age, Worldwide, 1997-2010 - In any remission, Acute Leukemia, CML or MDS- SUM12_34.ppt

15 100-day Mortality after Autologous Transplants, 2010 Slide 15 Mortality, % SUM12_35.ppt

16 100-day Mortality after HLA-identical Sibling Transplants, 2010 Slide 16 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % SUM12_36.ppt

17 100-day Mortality after Unrelated Donor Transplants, 2008-2009 Slide 17 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, % SUM12_37.ppt

18 Causes of Death after Transplants Done in 2009-2010 Autologous Infection (7%) Other (17%) Organ Failure (3%) New Malignancy (1%) Primary Disease (72%) Unrelated Donor Infection (18%) Other (18%) Organ Failure (8%) Primary Disease (37%) New Malignancy (1%) GVHD (18%) Slide 18 HLA-identical Sibling Infection (13%) Other (16%) Primary Disease (49%) GVHD (16%) Organ Failure (5%) New Malignancy (1%) SUM12_38.ppt

19 Allogeneic Transplants Registered with the CIBMTR, 2001-2010 - by Conditioning Regimen Intensity & Age - * * Data incomplete Slide 19 Number of Transplants SUM12_39.ppt

20 Allogeneic Transplants after Reduced- intensity Conditioning, by Donor Type, Registered with CIBMTR 1998-2010 Slide 20 Number of Transplants SUM12_40.ppt

21 One-Year Survival, % Slide 21 Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, 1998-2010 - by Year of Transplant & Disease - SUM12_41.ppt

22 Indications for Hematopoietic Stem Cell Transplants for Age 50yrs, in the U.S., 2010 SUM12_42.ppt Slide 22 Number of Transplants

23 Allogeneic Transplants in the U.S., Registered with the CIBMTR, 2007-2011 - by Donor Type - Slide 23 Transplants, % SUM12_43.ppt

24 SUM12_44.ppt Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipients by Group Age 2008-2011 Slide 24 Transplants, %

25 Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010 - By Disease Status - Years 026 13 45 Early (N=7,210) Intermediate (N=1,906) Advanced (N=2,923) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % SUM12_2.ppt Slide 25 P < 0.0001

26 Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010 - By Disease Status - Years 026 13 45 Early (N=5,364) Intermediate (N=3,374) Advanced (N=3.702) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % SUM12_3.ppt Slide 26 P < 0.0001

27 Survival after HLA-identical Sibling Donor Transplants for AML, Age 20 yrs, 2000-2010 - by Disease Status - Years 026 13 45 Early (N=1,292) Intermediate (N=268) Advanced (N=270) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % SUM12_4.ppt Slide 27 P < 0.0001

28 Probability of Survival after Autologous Transplants for AML, 2000-2010 - by Disease Status - Years 026 13 45 Early (N=2,139) Intermediate (N=735) Advanced (N=152) 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % SUM12_5.ppt Slide 28 P < 0.0001

29 Probability of Survival after Allogeneic Transplants for MDS, 2000-2010 - by Disease Status and Donor Type - SUM12_6.ppt Slide 29 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % Early, sibling donor (N=750) Early, unrelated donor (N=890) Advanced, sibling donor (N=1,407) Advanced, unrelated donor (N=1,660) P < 0.0001

30 Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20 yrs, 2000-2010 - by Disease Status - SUM12_7.ppt Slide 30 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Early (N=849) Intermediate (N=1,203) Advanced (N=210)

31 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20 yrs, 2000-2010 - By Disease Status - SUM12_8.ppt Slide 31 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Intermediate (N=2,034) Advanced (N=289) Early (N=977)

32 Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20 yrs, 2000-2010 - By Disease Status - Slide 32 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Intermediate (N=715) Advanced (N=584) Early (N=2,214) SUM12_9.ppt

33 Probability of Survival after Unrelated Donor Transplants for ALL, Age 20 yrs, 2000-2010 - By Disease Status - Slide 33 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Intermediate (N=1,075) Advanced (N=767) Early (N=1,818) SUM12_10.ppt

34 Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010 - By Disease Status and Transplant Year - Slide 34 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 CP, 1998-2000 (N=2,239) AP, 1998-2000 (N=291) CP, 2001-2010 (N=2,498) AP, 2001-2010 (N=360) SUM12_11.ppt

35 Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010 - by Donor Type and Conditioning Regimen Intensity - Slide 35 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Autologous transplant (N=270) Myeloablative conditioning (N=450) Reduced-intensity conditioning (N=871) SUM12_12.ppt

36 Probability of Survival after Allogeneic Transplants for SAA, 2000-2010 - By Donor Type and Age - Slide 36 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 20y, Sibling Donor (N=1,375) 20y, Sibling Donor (N=1,425) 20y, Unrelated Donor (N=654) 20y, Unrelated Donor (N=634) SUM12_13.ppt

37 Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010 - By Disease Status - Slide 37 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 CR (N=2,907) Not in CR, sensitive (N=3,832) Not in CR, resistant (N=1,237) SUM12_14.ppt

38 Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010 - By Conditioning Regimen and Donor Type - Slide 38 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P = 0.226 Sibling Donor (N=356) Unrelated Donor (N=205) SUM12_15.ppt

39 Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010 - By Disease Status - Slide 39 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Sensitive (N=2,676) Resistant (N=279) SUM12_16.ppt

40 Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2000-2010 - By Disease Status - Slide 40 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P = 0.002 Sensitive (N=840) Resistant (N=212) SUM12_17.ppt

41 Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010 - By Disease Status - Slide 41 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Sensitive (N=8,891) Resistant (N=1,033) SUM12_18.ppt

42 Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2000-2010 - By Disease Status - Slide 42 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Sensitive (N=503) Resistant (N=219) SUM12_19.ppt

43 Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010 - By Donor Type - Slide 43 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Sibling donor (N=554) Unrelated donor (N=389) Autologous (3,173) SUM12_20.ppt

44 Probability of Survival after Transplants for Multiple Myeloma, 2000-2010 - By Donor Type - Slide 44 Years 026 13 45 0 20 40 60 80 100 10 30 50 70 90 0 20 40 60 80 100 10 30 50 70 90 Probability of Survival, % P < 0.0001 Sibling Donor (N=892) Unrelated donor (N=380) Autologous (N27,979) SUM12_21.ppt

Download ppt "Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt."

Similar presentations

Numbers Treasure Hunt Following each question, click on the answer. If correct, the next page will load with a graphic first – these can be used to check.

Numbers Treasure Hunt Following each question, click on the answer. If correct, the next page will load with a graphic first – these can be used to check.
Un percorso realizzato da Mario Malizia

Un percorso realizzato da Mario Malizia
AP STUDY SESSION 2.

AP STUDY SESSION 2.
1

1
& dding ubtracting ractions.

& dding ubtracting ractions.
Copyright © 2003 Pearson Education, Inc. Slide 1 Computer Systems Organization & Architecture Chapters 8-12 John D. Carpinelli.

Copyright © 2003 Pearson Education, Inc. Slide 1 Computer Systems Organization & Architecture Chapters 8-12 John D. Carpinelli.
Copyright © 2011, Elsevier Inc. All rights reserved. Chapter 6 Author: Julia Richards and R. Scott Hawley.

Copyright © 2011, Elsevier Inc. All rights reserved. Chapter 6 Author: Julia Richards and R. Scott Hawley.
Author: Julia Richards and R. Scott Hawley

Author: Julia Richards and R. Scott Hawley
Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.

Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = 10 11 x 1 = 11 12 x 1 = 12 X 2 1.

Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = 10 11 ÷ 1 = 11 12 ÷ 1 = 12 ÷ 2 2 ÷ 2 =

Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
Objectives: Generate and describe sequences. Vocabulary:

Objectives: Generate and describe sequences. Vocabulary:
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.

OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
HEART-LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141.

HEART-LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26: 796-807.

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27: 937-983.

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.
David Burdett May 11, 2004 Package Binding for WS CDL.

David Burdett May 11, 2004 Package Binding for WS CDL.
We need a common denominator to add these fractions.

We need a common denominator to add these fractions.
1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.

1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.

Similar presentations

Ads by Google